Here we go. This phrase they have used about 2% inflation i have to dig it up. They say it in a weird way-- I have to find that phrase I think he may tweak it. The idea we need the stock market to get is the one I put forward over a year ago.. 3-4% inflation is the new 2%. So rather than point to continued path to 2% or whatever the Fed says-- he could give us a form of: inflation has been brought down from a unusually high level to a more moderate level where it may stay partially elevated for a number of years. For that reason interest rates will also stay higher than we are used to recently for a number of years but may be gradually reduced without achieving 2% inflation as long as the path of inflation continues to be down.<------ Bam! That's alot of words that the Fed would make into one sentence -- can we get that sentence/
The sticking point- For now, Fed chair Powell is probably pleased about the rise in the 10-year Treasury yield. That is contributing to higher rates for mortgages and auto loans, as well as pinched valuations for the S&P 500. In the real world people are still buying houses and getting mortgages because " they will just redo the loan refinance when rates come down " Boy that is a mega dangerous set up that the Fed must be clued into. The Fed likes these high rates.. but does he know about the China Gov selling? He must. If I have heard the rumors certainly he has. China has so much US bonds they could use this tactic as a weapon against our economy. This needs to be stopped and the only way to do that is to back away from these high rates that the Fed currently is enjoying.
Classic American story- The deal is expected to deliver a windfall to the relatives of Subway's two late founders, Fred DeLuca and Peter Buck - DANIEL LEAL The relatives of Subway’s founders are in line for billions of dollars after the sandwich chain was sold for a reported $9.6bn (£7.6bn). Subway announced on Thursday it had been bought by private equity firm Roark Capital Group, taking the fast-food chain out of family ownership for the first time in six decades. The deal is expected to deliver a windfall to the relatives of the company’s two late founders, Fred DeLuca and Peter Buck. Subway was founded in 1965 when 17-year-old DeLuca received a $1,000 loan from family friend Buck, a nuclear physicist 20 years his senior. He used the cash to open his first sandwich shop, then called Pete’s Super Submarines. Under DeLuca’s leadership, Subway overtook McDonald’s as the largest restaurant chain and now has about 37,000 franchise-run restaurants in more than 100 countries, including 2,100 in the UK. The duo boasted shared 50-50 ownership of Subway’s parent company, Doctor’s Associates, which takes as much 12pc in combined royalty and advertising fees from franchise owners, Forbes reported. Following Buck’s death in November 2021, his 50pc share of Subway was donated to his private family charity, the Peter and Carmen Lucia Buck Foundation. Carrie Schindele, executive director of the foundation, said at the time: “This gift will allow the Foundation to greatly expand its philanthropic endeavours and impact many more lives, especially our work to create educational opportunities for all students, work Dr Buck cared so deeply about.” The non-profit, founded by Dr Buck and his late wife Carmen Lucia in 1999, is run by sons Christopher and William, plus grandson Samuel, nephew Michael and sister-in-law Vera Lourenco. The other half of Subway belonging to Mr DeLuca, who died in 2015, is now reportedly wholly owned by his widow, Elisabeth. Following Mr DeLuca’s death, his younger sister Suzanne Greco took over as chief executive. However, she stepped down three years later after a series of restaurant closures. Subway’s current boss, John Chidsey, in 2019 became the company’s first chief executive from outside the family. Commenting on the sale, Mr Chidsey said: “Subway has a bright future with Roark, and we are committed to continuing to focus on a win-win-win approach for our franchisees, our guests and our employees.”
The Stock that is popping for me today in my mind is BLUEBIRD. Need to freshen up on the thesis.... Bluebird bio favored at Baird as sickle cell disease space gets busy BLUE+2.59% KEY POINTS Bluebird Bio has two approved gene-editing treatments, but they aren't generating much sales yet. The small-cap biotech company could earn another approval by the end of the year. Its next potential product has a much larger addressable market than its existing ones. Is this stock a value buy or a value trap? Looking at the performance of Bluebird Bio (BLUE2.59%)over the past three years, one wouldn't guess that it is one of the rare gene-editing specialists that has not just one but two approved products on the market in the U.S. The biotech's shares are down by 87% over this period. Is there any hope for Bluebird? Some think so. From its current share price of $3.42, Wall Street analysts believe the stock could jump by 115% within a year. Their average price target is $7.36. Meeting these expectations is one thing, but performing consistently well after that is another. Let's find out whether Bluebird's shares are worth buying while they are still down. All eyes on lovo-cel Bluebird is currently growing its revenue rapidly. The problem is that its sales are extremely low. In the second quarter, Bluebird's revenue of $6.9 million more than quadrupled compared to the year-ago period. The biotech's two approved gene-editing medicines are Zynteglo and Skysona. The former is a one-time curative treatment for transfusion-dependent beta-thalassemia (TDT), a rare blood disease. Skysona treats cerebral adrenoleukodystrophy (CALD), a rare, progressive, neurodegenerative disease. Aside from the fact that these therapies are difficult to administer and cost a lot of money, their combined target market in the U.S. is tiny -- about 1,540 patients. That's why Bluebird's next potential product is important. The company is awaiting approval from the U.S. Food and Drug Administration (FDA) for lovo-cel, a potential therapy for sickle cell disease (SCD), another rare blood disorder. The FDA set a Prescription Drug User Fee Act (PDUFA) action goal date (the latest date by which the FDA should either approve or decline Bluebird's application) of Dec. 20. Bluebird recently got more news from the regulatory agency. The FDA decided that there would not be an advisory committee meeting to discuss the approval of lovo-cel. Why does this matter? The health agency has its own experts who dig through the data from clinical trials and decide whether it is worth approving a medicine. However, the FDA occasionally requests the opinion of outside independent experts who also review all the facts and data and submit their recommendations. The FDA isn't obligated to follow the opinions of these independent experts, but it almost always does. However, it's important to highlight that the FDA often requests advisory committees "to assist the review division with interpretation when questions or difficulties related to trial data arise." That's why the FDA's decision not to hold an advisory committee meeting to discuss lovo-cel could be a good sign. There is always the possibility that the data so clearly does not support lovo-cel's efficacy that the FDA need not bother with independent experts singing the same tune, thereby wasting everyone's time. But that's unlikely. Bluebird argues that of all the gene therapies in development to treat SCD, lovo-cel is "the most deeply studied." The package that supports lovo-cel's approval includes data on more than 50 patients and a follow-up of more than six years for some patients (that's a lot), the longest follow-up time of any gene therapy for SCD. NASDAQ: BLUE Bluebird Bio Today's Change (2.59%) $0.09 Current Price $3.56 Lovo-cel's market opportunity With lovo-cel looking increasingly likely to earn approval, let's turn to the medicine's market opportunity. Bluebird estimates 20,000 eligible patients in the U.S. The company couldfairly price lovo-cel at about $2 million, which is even less than what its current therapies cost. Zynteglo is priced at $2.8 million per-treatment course, while Skysona costs $3 million. Lovo-cel's total addressable market could amount to more than $40 billion for a company with a market cap well below $1 billion. But there's a catch. First, lovo-cel will encounter some of the same issues as Zynteglo and Skysona. It is complex to administer and can only be done in qualified treatment centers. Second, there is another treatment for SCD on the way.Vertex Pharmaceutical andCRISPR Therapeuticsare awaiting FDA approval for exa-cel, a competing medicine. The FDA should decide on this therapy by Dec. 8. Vertex has more funds to work with than Bluebird. On the other hand, lovo-cel received a B+ grade from The Institute for Clinical and Economic Review (ICER), a non-profit organization concerned with ensuring the affordability of medical care. The ICER gave a grade of C++ to exa-cel. So, at least according to this organization -- the same one that estimated a fair price for these medicines of as much as $2 million -- lovo-cel seems slightly more effective than its would-be competitor. Let's assume Bluebird can capture a 20% share of its target market of about 20,000 patients in the next 10 years. That's $8 billion, or an average of $800 million annually. Is Bluebird stock a buy? There is a lot that can still go wrong for Bluebird. But at the very least, the company has proven innovative capabilities. If enough can go right for the company, it could far exceed Wall Street's expectations even through the next year. Bluebird's shares could soar on lovo-cel's approval. But Bluebird remains a very risky stock as investors will be left with worthless shares if anything goes wrong with lovo-cel.
--Citi sees 'compelling opportunity' in LegalZoom after meetings » 06:55 LZ I'm rooting for this company. It's them vs Chatbots GP....
Meta launches AI model for coding Is AI the Fed's best friend? How many folks are going to lose their jobs. Coders? First in line. All these kids have gone to school recently to learn coding... There are coding summer camps.. All these young folk.....
I show Petrobras as having no dividend. This news story is weird: Petrobras upgraded to Buy at UBS, seeing 20% dividend yield potential for 2024 Aside from that the stk looks good on a chart. It has had a very strong 6 month run in the face of oil stks lagging. Brazil is a hot spot for investment. Newsflow- Petrobras expects another 40 years of oil production, exec says Petrobras surges as Brazil's attorney general opens path to explore Amazon area Petrobras: Political Risk Is Decreasing, Brace For Re-Rating I view PBR as a channel stock- that channel being $10-$15/ Now at the top end of that channel I would not buy. At near $10 and if they bring on a hefty div... I'm certainly interested. That Amazon exploration has to be hands off the rain forest.
Very slow news day. One thought i have is on Foot locker. I wanted to see if there was any buying afterthe sellofff and their was some- $15--$17 not alot granted but some... as well--> Unusual call flow in option market yesterday » 07:35 FL I have only 1 fund and it's a behavioral value fund and when the next annual report comes in I bet ya they scooped FL. It's just their type. The scary thing after the free fall- the PE it's in line with past years!!! Ayyyyyyyy. But although not exciting at all... you could make the case that we are at a trough here... and in your IRA you might take a stab at FL soon.
I did a tic by tic look and Wed 9:45 in the free fall right near the bottom there was a very large 4.1M positive vol surge-- a few mutual funds most likely.
Speaking of ticks. Folks are freaking out about a new tick virus up here that hits you in a matter of hours and sends folks straight to the hospital.. Lime Disease we know is a horrible problem. GSK is bringing a vaccine to market. I think that's big news. Who is GSK you aas? I had to look... Description GSK plc, together with its subsidiaries, engages in the research, development and manufacture of vaccines and specialty medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as infectious disease, HIV, immunology and respiratory, and oncology. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is based in Brentford, the United Kingdom. Who is the idiot who decided GSK was a better name than Glaxo SmithKline a great name. Big pic large double top at $48--$50 but hard times! >>>>>> Currently $34.50.